Creator: Help Dementia Editorial Team
Published: 2026-06-17T06:04:48

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Advanced dementia sits at the center of this dementia and brain health question.

The short answer is: not much yet. Current FDA-approved dementia drugs like lecanemab and donanemab work only in early-stage disease and do not slow decline in advanced Alzheimer’s dementia. For patients already in moderate to severe stages, there are no disease-modifying treatments available—only symptomatic therapies like memantine that manage symptoms without addressing the underlying disease. However, the research landscape is shifting rapidly. Clinical trials are underway for new drug candidates specifically designed to tackle advanced-stage disease, though none have yet proven effective enough to earn FDA approval for these later stages.

This gap exists because advanced dementia presents a fundamentally different biological challenge. By the time patients reach moderate to severe stages, amyloid plaques and tau tangles have caused widespread structural damage to the brain. Single-target drugs that worked in early disease—attacking just amyloid or just inflammation—are insufficient to reverse that damage. Researchers increasingly believe that treating advanced dementia will require combination therapies that address multiple disease pathways simultaneously. With 9 Phase 3 clinical trials currently testing drugs specifically for severe Alzheimer’s disease, the field is actively pursuing solutions for patients who currently have no options.

What Treatment Options Currently Exist for Advanced Dementia?
The Limitations of Single-Target Therapies in Late-Stage Disease
Approved Drugs: Why They Work for Early Stages but Not Advanced Cases
The Future Pipeline: New Drugs Being Tested for Advanced Dementia
Combination Therapies and Why Multiple Drug Approaches May Be Necessary
What This Means for Caregivers and Families Right Now
The Timeline for New Advanced Dementia Treatments

What Treatment Options Currently Exist for Advanced Dementia?

Today, the medication arsenal for advanced dementia is remarkably thin. Memantine is the primary drug prescribed to patients in moderate and severe stages. Unlike the newer amyloid-targeting drugs, memantine is purely symptomatic—it doesn’t slow the underlying disease progression but can help preserve some cognitive function and reduce behavioral symptoms like agitation or aggression. Doctors have used it for nearly two decades because, frankly, there’s little else to offer. Some patients also take cholinesterase inhibitors like donepezil, which work by boosting acetylcholine levels in the brain, but again, these manage symptoms rather than modify disease course.

The stark difference between early-stage and advanced-stage options illustrates a major problem in dementia research. Lecanemab, approved in 2023 for mild cognitive impairment or early Alzheimer’s disease, reduced cognitive decline by 27% after 18 months in the landmark CLARITY AD trial involving 1,795 patients. Donanemab, approved in 2024, shows similar benefits for early-stage patients. But neither drug has been studied or approved for moderate or severe disease. The pharmaceutical companies haven’t pursued those populations because the biological mechanisms that make these drugs work in early disease—targeting amyloid before widespread neurodegeneration occurs—are far less effective once the brain is already severely damaged.

The Limitations of Single-Target Therapies in Late-Stage Disease

The central limitation of current dementia drugs is that they are too narrowly focused. Both lecanemab and donanemab target amyloid-beta accumulation, which is a primary driver of early Alzheimer’s disease. However, in advanced dementia, the disease has progressed far beyond amyloid. By this stage, tau tangles are widespread, neuroinflammation is chronic, mitochondrial dysfunction is severe, and neuronal connections have already been destroyed. Attacking amyloid alone cannot reverse this level of damage or restore lost brain tissue.

This is why the research community has increasingly concluded that advanced dementia will require combination therapies—drugs that simultaneously target multiple pathways. A single mechanism is simply insufficient. Consider the difference between catching a fire in the attic (early disease, single amyloid pathology) versus a fully engulfed building (advanced disease, multiple systems failing). You cannot extinguish a raging fire with one type of equipment. The same principle applies to treating late-stage dementia. Researchers are now testing combinations of 25+ drugs together in various trials, addressing amyloid, tau, inflammation, neuronal death, and other pathways at once.

Approved Drugs: Why They Work for Early Stages but Not Advanced Cases

Lecanemab and donanemab share a common mechanism: they are monoclonal antibodies that bind to amyloid-beta and accelerate its clearance from the brain. In the CLARITY AD trial, lecanemab slowed cognitive decline by 27% in patients with mild cognitive impairment or early Alzheimer’s—meaningful but not transformative. These drugs work in early disease because amyloid accumulation is the primary pathology driving neurodegeneration at that stage. Removing amyloid can prevent or slow the downstream cascade of damage. But in advanced dementia, amyloid removal alone has limited impact.

By the time patients reach moderate or severe stages, their brains have already experienced years of continuous damage. Synapses are lost, neurons are dead, and the disease has evolved beyond amyloid-only pathology. Amyloid-targeting monoclonal antibodies cannot restore dead neurons or rebuild lost connections. Additionally, these drugs come with a significant risk: amyloid-related imaging abnormalities (ARIA), which are microhemorrhages or microinfarcts visible on brain MRI. The benefit-to-risk ratio of these drugs in late-stage patients—where disease-modifying potential is already low—becomes unacceptable. This is why neither lecanemab nor donanemab has been pursued for advanced dementia populations.

The Future Pipeline: New Drugs Being Tested for Advanced Dementia

The pharmaceutical pipeline for advanced dementia includes several novel approaches currently in Phase 3 clinical trials. Blarcamesine represents one strategy: instead of targeting amyloid or tau directly, it enhances the brain’s glial clearance system—essentially improving the brain’s ability to clean itself of toxic debris. Buntanetap (from Annovis) takes a different approach, targeting protein translation to reduce accumulation of pathogenic proteins.

Both drugs are designed to address disease mechanisms that persist in advanced stages. Other candidates being tested include etalanetag, which shows promise specifically for inherited Alzheimer’s disease, and neflamapimod, which targets inflammation in dementia with Lewy bodies—a different dementia subtype that often co-occurs with Alzheimer’s pathology in advanced disease. The fact that 9 Phase 3 trials are actively recruiting or enrolling patients with severe Alzheimer’s indicates that researchers have not abandoned advanced-stage disease, but they are testing fundamentally different approaches than the amyloid-targeting monoclonal antibodies that worked in early disease. The timeline remains uncertain—regulatory approval for any of these drugs is likely years away.

Combination Therapies and Why Multiple Drug Approaches May Be Necessary

Perhaps the most significant shift in dementia research is the move toward combination drug regimens. Approximately 25 drugs are currently being studied in combination trials, attacking multiple biological pathways simultaneously. This approach recognizes that advanced dementia is not a single-disease problem but rather a convergence of multiple failures: amyloid accumulation, tau pathology, neuroinflammation, mitochondrial dysfunction, and loss of synaptic plasticity. No single drug can address all of these at once. The challenge with combination therapy is complexity.

Regulatory pathways for approving drug combinations are less established than for single agents. Dosing and drug interactions must be carefully studied. Tolerability becomes harder to predict when multiple active compounds are in the bloodstream. However, the biological reality may force this path. If single-target therapies cannot reverse advanced dementia, then the field has little choice but to tackle multiple targets. Some researchers estimate that the first successful disease-modifying treatments for advanced Alzheimer’s may involve three or more drugs used together, though this remains speculative at present.

What This Means for Caregivers and Families Right Now

For families caring for someone in moderate or severe dementia, the current reality is sobering. No new drug will reverse the disease or restore lost cognitive function. Memantine and symptom-management medications remain the standard of care, offering modest support for quality of life but not disease modification.

If a family member is enrolled in a clinical trial for an advanced-stage drug, that trial offers hope and the possibility of contributing to science, but success is not assured. What families can control is symptom management, behavioral support, and maintaining physical and cognitive engagement. A structured environment, meaningful activities, consistent caregiving, and good medical management of comorbidities (infections, pain, sleep disruption) often have more impact on quality of life than any single medication. Families should also advocate for their loved one to be considered for clinical trials, as participation may eventually lead to access to new drugs before FDA approval, and trial data are essential for advancing the field.

The Timeline for New Advanced Dementia Treatments

The transition from Phase 3 trial to FDA approval typically takes two to three years, assuming successful trial results. With 9 Phase 3 trials currently underway for severe Alzheimer’s disease, it is plausible that the first disease-modifying drug for advanced dementia could reach the market by 2027 or 2028, but this is optimistic. More conservative estimates place approval of any new drug for advanced stages in the late 2020s or early 2030s. Failure is also possible—most drugs in Phase 3 trials do not ultimately succeed.

Additionally, early success in a trial does not guarantee that a drug will be effective across the entire advanced-dementia population, as dementia heterogeneity is substantial. The research community understands that advanced-stage disease remains particularly challenging to treat. The brain damage is already extensive, and reversing that damage is biologically harder than preventing it. This is why early detection and early-stage treatment with approved drugs like lecanemab remain the most effective strategy today. For patients already in moderate to severe stages, awareness of ongoing trials and realistic expectations about timing and efficacy are crucial for informed decision-making.